display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 1st line (L1)la/mBC - HR positive - L1 - PIK3CA mutant
AKT inhibitor
capivasertib based treatment
capivasertib plus paclitaxel BEECH
ipatasertib based treatment
ipatasertib plus paclitaxel IPATunity130

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons